| July 10, 2014 | ISSUE NUMBER 359 VOL 4 |
Brand Reputation
Capturing the Real Value from a Pharma Spinout
The pharma spin market is poised to move into high gear as companies see the imperative to tap corporate brand value to retain shareholder confidence. Allen Gove explains how understanding what the company is about is critical to bolstering the value of the product ...Read more
Compliance
Open Payments: A New Dawn for Transparency
The Physicians Payment Sunshine Act, more formally referred to as Open Payments, has been in place for almost 18 months. It is only in the next few months, however, that the implications of the law and its contentious requirements will start to be fully realized. Michael Christel reports
...Read more
The lifecycle of a new product is shorter, more contested, full of regulatory delays, and beset by a challenging access and reimbursement environment. Learn how to wrest maximum value from every stage of the lifecycle – from access to acquisition to adherence –
 by downloading this eBook
.
Regulatory
Opioids: Don’t Fix the Blame, Fix the Problem
Google "opioid abuse deterrence" and you'll find a lot of hits from lawyers and officials. What you won't find is a lot of expert thinking from FDA. That needs to change, says Peter J. Pitts, President of the Center for Medicine in the Public Health
...Read more
Regulatory
FDA’s Patient Outreach: Finding the Ties That Bind
Is the FDA doing enough to incorporate the patient perspective in the drug review process? This was the key question considered at a panel of regulatory experts held at last month's annual BIO International Convention in San Diego. The consensus: more needs to be done. William Looney reports
...Read more
Report
Product Cycle Strategies for Greater Profitability
In this compilation of four in-depth, data-rich reports from Pharmaceutical Executive, you'll learn a new set of metrics allowing companies to align their strategies around the push for greater profitability, putting them on the right track ...Click here to order |
|
|
|
 //Provista Diagnostics, Inc. (New York, NY) appointed Rao V. Mulpuri, Ph.D, MBA, as Chief Operating Officer.//Aerie Pharmaceuticals, Inc. (Bridgewater, NJ) announced that Michael McCleerey has been appointed to the newly established position of Vice President, Marketing.//Arch Therapeutics, Inc. (Wellesley, MA) appointed Richard Davis as Chief Financial Officer.//Raptor Pharmaceuticals, Inc. (Novato, CA) has named Executive Vice President, Strategy, and Chief Operating Officer Julie Ann Smith as President and CEO-designate, effective immediately.//Vitae Pharmaceuticals, Inc. (Fort Washington, PA) announced that Art Fratamico, MBA, has been named Chief Business Officer and Richard Morris, CPA, has joined the company as Chief Financial Officer.// |
|
|
|
|
|
 |
|
|
| |
|
| |
|
 |
|
 |
What is pharma’s most pressing digital challenge?
|
|
|
|
